Immune‐related adverse events in cancer patients being treated with immune checkpoint inhibitors
- 28 August 2021
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 107 (6) , 650-657
Abstract
Introduction: With the increased use of immune checkpoint inhibitors (ICI), it is essential to improve our understanding of immune‐related adverse events (irAE). To date, most studies describing irAE have been performed in clinical trial populations, which may not be an accurate description of irAE in real‐world populations. Also, identification of patients at increased risk of irAE is needed as early recognition may improve irAE outcomes.Methods: We performed a retrospective analysis of patients who received an ICI between January 2014 and October 2018 at a single institution (Tufts Medical Center). Each patient was followed for up to 12 months for the outcome of a physician‐reported irAE. Kaplan‐Meier curves were created for the time to development and resolution of initial irAE. A Cox proportional hazards model was created to evaluate whether the following variables were independent predictors of an initial irAE: age ≥65 years, female sex, non‐Caucasian race, radiation in previous 6 months, current smoking status, melanoma, and combination ICI (ipilimumab and nivolumab).Results: Of 131 patients followed, 57 patients (43.5%) developed at least one irAE at a median of 250 days (95% confidence interval (CI) 132 days‐not estimable). The most common irAE included dermatitis, thyroid dysfunction, and pneumonitis. Nearly two‐thirds of patients with an irAE had ICI therapy withdrawn, and nearly 60% had immunosuppression initiated. In multivariable analysis, we found a significant association between irAE development and age ≥65 years hazard ratio (HR) 1.80, 95% CI (1.03‐3.14) and current smoking status (HR 2.26, 95% CI 1.06‐4.82).Discussion: We detected a high rate of irAE and that irAE and subsequent management can be clinically burdensome in this patient population. While further studies are needed to validate these findings, this study provides insights into the magnitude, time course, management of, and possible predictors of irAE in a real‐world setting.Keywords
This publication has 41 references indexed in Scilit:
- Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin LymphomaJournal of Clinical Oncology, 2017
- Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer PatientsCancer Immunology Research, 2017
- The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trialsEuropean Journal of Cancer, 2017
- Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced CancerJAMA Oncology, 2016
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine, 2016
- Cancer immunotherapy in patients with preexisting autoimmune disordersSeminars in Immunopathology, 2016
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trialThe Lancet Oncology, 2016
- Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2016
- Effects of cigarette smoke on the immune systemNature Reviews Immunology, 2002
- Toxicity and response criteria of the Eastern Cooperative Oncology GroupAmerican Journal of Clinical Oncology, 1982